<DOC>
	<DOCNO>NCT01443221</DOCNO>
	<brief_summary>To investigate safety pharmacokinetics mitiglinide metformin fixed-dose combination mitiglinide/metformin , compare free combination mitiglinide metformin healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetics Mitiglinide Metformin Free Combination Fixed-dose Combination Healthy Male Subjects .</brief_title>
	<detailed_description>The Korean clinical practice guideline DM recommend second oral agent different mechanism action combine regimen adequate glycemic control difficult achieve oral hypoglycemic agent accompany dietary therapy . Therefore , concurrent administration metformin , inhibitor gluconeogenesis , mitiglinide , insulin secretagogue , could effective ideal regimen management diabetes .</detailed_description>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy male Subject adequate clinical laboratory test result ( hematology , blood chemistry , serology , drug abuse , urinalysis etc . ) Subject normal result blood pressure , pulse , body temperature ECG test Subject body mass index ( BMI ) 18.5 kg/m2 25 kg/m2 Clinically significant functional disorder acute disease Chronic disease affect absorption , metabolism excretion drug Any study drug administration within 90 day first drug administration Use medicine affect drug metabolism ( inhibition , induction ) barbital , within 30 day first drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>mitiglinide</keyword>
	<keyword>metformin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>